MedTrace Logo

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

NCT06189391 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-03-19

No results posted yet for this study

Summary

Researchers are looking for new ways to treat people with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). B-cells are a type of white blood cells that make antibodies and help fight infections. Non-Hodgkin Lymphoma is a type of cancer in the lymphatic system causing enlarged lymph nodes and/or organs in belly or chest. Relapsed means a disease or condition comes back after treatment Refractory means a disease does not respond to treatment or stops responding to a treatment.

MK-1045, the study medicine, is designed to treat relapsed or refractory B-NHL. MK-1045 is an immunotherapy, which is a treatment that helps the immune system fight cancer.

This is the first study in which MK-1045 will be given to people. The goal of this study is to learn about:

* The safety of MK-1045 and how well people tolerate it.
* The highest dose of MK-1045 that is well tolerated.
* How well MK-1045 works to treat relapsed or refractory B-NHL.

Conditions

  • Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Interventions

DRUG

MK-1045

IV infusion

Sponsors & Collaborators

  • MSD R&D (China) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Merck Sharp and Dohme LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-16
Primary Completion
2028-09-30
Completion
2029-03-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06189391 on ClinicalTrials.gov